FR2398051B1 - - Google Patents

Info

Publication number
FR2398051B1
FR2398051B1 FR7821686A FR7821686A FR2398051B1 FR 2398051 B1 FR2398051 B1 FR 2398051B1 FR 7821686 A FR7821686 A FR 7821686A FR 7821686 A FR7821686 A FR 7821686A FR 2398051 B1 FR2398051 B1 FR 2398051B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7821686A
Other languages
French (fr)
Other versions
FR2398051A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP8855677A external-priority patent/JPS5424868A/ja
Priority claimed from JP11424277A external-priority patent/JPS5446776A/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of FR2398051A1 publication Critical patent/FR2398051A1/fr
Application granted granted Critical
Publication of FR2398051B1 publication Critical patent/FR2398051B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR7821686A 1977-07-22 1978-07-21 Nouveau fragment du glucagon et ses derives Granted FR2398051A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8855677A JPS5424868A (en) 1977-07-22 1977-07-22 Novel glucagon fragment
JP11424277A JPS5446776A (en) 1977-09-21 1977-09-21 Novel peptide

Publications (2)

Publication Number Publication Date
FR2398051A1 FR2398051A1 (fr) 1979-02-16
FR2398051B1 true FR2398051B1 (enExample) 1983-09-16

Family

ID=26429925

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7821686A Granted FR2398051A1 (fr) 1977-07-22 1978-07-21 Nouveau fragment du glucagon et ses derives

Country Status (4)

Country Link
US (1) US4206199A (enExample)
DE (2) DE2858718C2 (enExample)
FR (1) FR2398051A1 (enExample)
GB (1) GB2002387B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5539702A (en) * 1978-08-30 1980-03-19 Takeda Chem Ind Ltd Method of measuring enzyme immunity of pancreas glucagon
JPS5657753A (en) * 1979-10-16 1981-05-20 Toyo Jozo Co Ltd Novel glucagon fragment, and its use
JPS56163456A (en) * 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) * 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US5693741A (en) 1988-03-15 1997-12-02 The Boeing Company Liquid molding compounds
US4430326A (en) 1981-12-22 1984-02-07 University Patents, Inc. Method of diminishing glucose levels resulting from endogenous glucagon
GB2160312B (en) * 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
FR2602679B1 (fr) * 1986-08-14 1989-02-24 Inst Nat Sante Rech Med Nouvelles compositions pharmaceutiques renfermant comme principe actif regulateur du mouvement des ions calcium un fragment du glucagon, et preparation d'un tel fragment
US5089390A (en) * 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20060223767A1 (en) * 2003-01-10 2006-10-05 Haruo Hanawa Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene therapy
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
EP3194441A1 (en) 2014-09-16 2017-07-26 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
SG10201913074WA (en) 2016-08-30 2020-03-30 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US12139546B2 (en) 2017-08-22 2024-11-12 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643345C3 (de) * 1967-08-19 1975-09-25 Hoechst Ag, 6000 Frankfurt Glucagonderivat und Verfahren zur Herstellung von Glucagon
FR1584386A (enExample) * 1967-08-19 1969-12-19
US3979506A (en) * 1974-10-11 1976-09-07 Pierce Chemical Company Radioactive compounds for labeling proteins

Also Published As

Publication number Publication date
DE2832090A1 (de) 1979-02-08
DE2858718C2 (enExample) 1989-07-06
FR2398051A1 (fr) 1979-02-16
US4206199A (en) 1980-06-03
GB2002387B (en) 1982-02-10
DE2832090C2 (enExample) 1989-07-20
GB2002387A (en) 1979-02-21

Similar Documents

Publication Publication Date Title
FR2377376B1 (enExample)
FR2377589B1 (enExample)
FR2376420B1 (enExample)
FR2377460B1 (enExample)
FR2378221B1 (enExample)
FR2378152B1 (enExample)
DK139563C (enExample)
AR210643A1 (enExample)
AU71461S (enExample)
BG25829A1 (enExample)
BG25824A1 (enExample)
BG25823A1 (enExample)
BG25850A1 (enExample)
BG25837A1 (enExample)
BG23462A1 (enExample)
BE865722A (enExample)
BG25839A1 (enExample)
BE872973A (enExample)
BG25860A1 (enExample)
BG25845A1 (enExample)
BG25827A2 (enExample)
BG25819A1 (enExample)
BG25826A1 (enExample)
BE871991A (enExample)
BE866391A (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse